Who owns Atyr Pharma Inc?
- Ticker: LIFE
- CUSIP Number: 002120202
Tip: Access positions for across all investors
Analyze quarterly positions in Atyr Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Atyr Pharma stock
Who bought or sold Atyr Pharma Inc this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Federated Investors | 10M | $14M | 0% | Dec 2023 |
|
FMR | 8.6M | $14M | 5% | Sep 2023 |
|
Logos Global Management | 5.9M | $8.2M | 100% | Dec 2023 |
|
Stonepine Capital Management | 4.6M | $7.3M | 0% | Sep 2023 |
|
Tikvah Management | 2.5M | $3.9M | 0% | Sep 2023 |
|
Alyeska Investment Group | 2.5M | $3.5M | 0% | Dec 2023 |
|
Vanguard Group | 2.4M | $3.3M | 4% | Dec 2023 |
|
Citadel Advisors | 1.8M | $2.5M | -2% | Dec 2023 |
|
Checkpoint Capital | 1.5M | $2.1M | 100% | Dec 2023 |
|
BlackRock | 1.4M | $2.1M | -1% | Sep 2023 |
|
Geode Capital Management | 587k | $928k | -1% | Sep 2023 |
|
Renaissance Technologies | 506k | $799k | -4% | Sep 2023 |
|
Tang Capital Management | 471k | $664k | 0% | Dec 2023 |
|
State Street Corporation | 167k | $264k | 0% | Sep 2023 |
|
Bank of America Corporation | 149k | $210k | 128141% | Dec 2023 |
|
Two Sigma Advisers | 148k | $208k | -22% | Dec 2023 |
|
Goldman Sachs Group | 144k | $202k | 100% | Dec 2023 |
|
Dimensional Fund Advisors | 142k | $201k | -40% | Dec 2023 |
|
Millennium Management | 125k | $177k | 49% | Dec 2023 |
|
Squarepoint Ops | 120k | $168k | -15% | Dec 2023 |
|
GSA Capital Partners | 109k | $154k | 296% | Dec 2023 |
|
Royal Bank of Canada | 91k | $0 | 13% | Dec 2023 |
|
Barclays | 79k | $111k | 100% | Dec 2023 |
|
Citigroup | 79k | $111k | 100% | Dec 2023 |
|
Northern Trust | 79k | $124k | -32% | Sep 2023 |
|
XTX Topco | 74k | $117k | -57% | Sep 2023 |
|
Pale Fire Capital SE | 56k | $88k | 100% | Sep 2023 |
|
Boothbay Fund Management | 36k | $57k | 0% | Sep 2023 |
|
Farther Finance Advisors | 30k | $43k | 100% | Dec 2023 |
|
Charles Schwab Investment Management | 27k | $38k | 0% | Dec 2023 |
|
Two Sigma Investments | 27k | $37k | -71% | Dec 2023 |
|
Virtu Financial | 26k | $37k | 93% | Dec 2023 |
|
American Century Companies | 22k | $35k | 56% | Sep 2023 |
|
Granite Bay Wealth Management | 18k | $22k | 100% | Dec 2023 |
|
Cubist Systematic Strategies | 18k | $25k | 47% | Dec 2023 |
|
Bank of New York Mellon | 16k | $23k | 0% | Dec 2023 |
|
UBS Group | 16k | $23k | 273% | Dec 2023 |
|
D.A. Davidson & Co. | 13k | $18k | -44% | Dec 2023 |
|
Jpmorgan Chase & Co | 12k | $17k | -76% | Dec 2023 |
|
Actinver Wealth Management | 10k | $14k | 0% | Dec 2023 |
|
Morgan Stanley | 2.4k | $4.8k | -2% | Sep 2023 |
|
Wells Fargo & Company | 1.9k | $2.7k | 2% | Dec 2023 |
|
Tower Research Capital | 682.00 | $1.1k | 223% | Sep 2023 |
|
PFS Partners | 340.00 | $480.012000 | -15% | Dec 2023 |
|
Qube Research & Technologies | 188.00 | $297.002400 | 100% | Sep 2023 |
|
Caldwell Sutter Capital | 52.00 | $72.997600 | 0% | Dec 2023 |
|
Who sold out of Atyr Pharma?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Man Group | Sep 2023 | 421k | $666k |
Susquehanna International | Jun 2023 | 126k | $272k |
Wolverine Trading | Sep 2023 | 11k | $17k |
Simplex Trading | Sep 2023 | 9.0k | $14k |